In a report published Wednesday, Morgan Stanley analyst David Friedman downgraded Neurocrine Biosciences, Inc. NBIX to EW from OW, raising its price target to $16.00.
According to the report, the price target increase is based on a set of model changes including adding VMAT sales. The downgrade is due to the recent stock appreciation.
“While we expect clinical and commercial success for Elagolix in both endometriosis and uterine fibroids, we are changing our rating from OW to EW based on a seemingly more balanced risk-reward with the stock at current levels,” the report noted. “We have made a series of model changes, including adding '854 (VMAT) sales to our model in light of the recent, albeit somewhat modest benefit shown in the KINECT 2.”
NBIX closed Tuesday at $18.51 with shares trading up 89.69 percent.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorDowngradesAnalyst RatingsBiotechnologyDavid FriedmanHealth CareMorgan Stanley
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in